GLP-1 drugs can increase the risk of gallstones. The analysis of gallstones and reflux in 55 randomized trials estimated a gallstone risk ratio of 1.46 (95% CI 1.09–1.97), or about two extra cases per 1,000 people compared with placebo.[2]
What the diabetes cohort found
Researchers matched 39,140 GLP-1 users with 39,140 controls, all adults with type 2 diabetes. At two years, stones in the gallbladder or bile duct were recorded in 440 users (1.13%) and 307 controls (0.79%). The adjusted odds ratio was 1.44 (95% CI 1.24–1.65). At three years it was 1.43 (95% CI 1.24–1.63). Gallbladder inflammation also had higher adjusted odds at three years (1.45, 95% CI 1.14–1.83).[1]
Participants taking GLP-1 drugs had more abdominal imaging, which may have led to more diagnoses of otherwise unnoticed stones. The groups also differed in baseline BMI despite matching. The randomized trials and the cohort both found an increase in stone diagnoses, each with its own population and measure.[1][2]
What the study found about surgery
At two years, gallbladder removal had an adjusted odds ratio of 1.13 (95% CI 0.84–1.54). At three years, 134 GLP-1 users and 87 controls had undergone removal (adjusted odds ratio 1.54, 95% CI 1.17–2.02). Those assessments show when the difference was detectable in this study. They cannot establish when a medication-related risk begins.[1]
Acute pancreatitis and endoscopic bile-duct procedures showed no statistically significant difference at either assessment. Research on GLP-1 use after an episode of pancreatitis addresses a separate question about recurrence. Comparisons by drug in the gallbladder cohort also cannot establish which medication is safest.[1]